8-K

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                          ---------------------------


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                        SECURITIES EXCHANGE ACT OF 1934


                               SEPTEMBER 14, 2004
                Date of Report (Date of earliest event reported)


                          DISCOVERY LABORATORIES, INC.
             (Exact name of Registrant as specified in its charter)


         DELAWARE                   000-26422                94-3171943
      (State or other       (Commission File Number)        (IRS Employer
       jurisdiction                                    Identification Number)
     of incorporation)


                           350 MAIN STREET, SUITE 307
                         DOYLESTOWN, PENNSYLVANIA 18901
                    (Address of principal executive offices)


                                 (215) 340-4699
              (Registrant's telephone number, including area code)


         (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[_]  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)
[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)
[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))
[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))



ITEM 5.02.  DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF
            DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS

On September 14, 2004, Discovery Laboratories, Inc. (the "Company") appointed W.
Thomas Amick to its Board of Directors.  Prior to his appointment as a member of
the Board,  Mr. Amick served as a  commercialization  strategist  to the Company
since March 1, 2004.  In such role,  Mr. Amick  received  cash  compensation  of
$60,000  and options to purchase  25,000  shares of common  stock of the Company
pursuant to the terms and  conditions of the Company's 1998 Amended and Restated
Stock Incentive Plan. The Company issued a press release  announcing Mr. Amick's
appointment  on September  14, 2004.  The full text of the press  release is set
forth in Exhibit 99.1 hereto.


ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBITS

            (c)   Exhibits:

            99.1  Press Release dated September 14, 2004.


                                       2


                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.



                                          DISCOVERY LABORATORIES, INC.


                                          By:   /s/ Robert J. Capetola,
                                              --------------------------------
                                          Name:  Robert J. Capetola, Ph.D.
                                          Title: President and Chief Executive
                                                   Officer

Date: September 20, 2004


                                       3

EX-99.1

                                                                    EXHIBIT 99.1


           W. THOMAS AMICK, FORMER J&J SENIOR EXECUTIVE, APPOINTED TO
                       DISCOVERY LABS' BOARD OF DIRECTORS

DOYLESTOWN,  PA -- SEPTEMBER 14, 2004 -- DISCOVERY  LABORATORIES,  INC. (NASDAQ:
DSCO),  today  announced  the  appointment  of W.  Thomas  Amick to its Board of
Directors. Mr. Amick adds global commercial and strategic expertise to Discovery
as the Company prepares for the potential commercialization of its lead product,
Surfaxin(r),  for the  prevention  of  Respiratory  Distress  Syndrome  (RDS) in
premature infants and advances its pipeline of Surfactant  Replacement Therapies
for the treatment of various respiratory diseases.

Mr.  Amick  brings  more  than 30  years  of  pharmaceutical  and  biotechnology
experience as an executive  with Johnson & Johnson,  with specific  expertise in
building and leading commercial  operations throughout North America and Europe.
Mr.  Amick's   positions   included   President  of  Ortho  Biotech  Europe  and
Janssen-Ortho Canada and Worldwide Vice President of J&J's Oncology Group, where
he created and managed the  commercial  organizations  for J&J's first  oncology
franchise within Ortho Biotech.  Mr. Amick was also responsible for building the
organization  that  drove  the  growth  of  Procrit  into a  multibillion-dollar
product.

Robert J. Capetola,  Ph.D.,  President and Chief Executive  Officer of Discovery
Laboratories  stated,  "Tom brings to Discovery's Board extensive  experience in
the commercialization of several  successfully-marketed  products, many of which
set new treatment  standards or established new treatment paradigms within their
therapeutic   areas.   This   experience   is   beneficial   to  executing   our
commercialization  strategy. If approved,  Surfaxin will represent a significant
opportunity  to improve the  standard of care for  premature  infants who suffer
from RDS."

"Discovery's   mission  is  to  advance  to  market  a  pipeline  of  Surfactant
Replacement  Therapies  which we believe  will  revolutionize  the  treatment of
respiratory  diseases.  The  introduction  of  Surfaxin  has  the  potential  to
represent a dramatic  evolution in the role  surfactants play in the neonatology
community and could become the first engineered  humanized  surfactant available
throughout  the world.  Our strategy is to build a  therapeutic  portfolio  that
addresses the range of respiratory  disorders treated in the NICU, critical care
and  hospital  settings.  Tom  brings a wealth of  operational  experiences  and
pharmaceutical  industry  relationships  that  are  essential  to  properly  and
carefully execute this strategy," continued Dr. Capetola.

Mr. Amick received a B.S. Degree in Business from Elon University. Additionally,
he has completed  graduate courses at the Darden Business School,  University of
Virginia,  the Kellogg  School of  Business,  Northwestern  University,  and the
Harvard Business School.



ABOUT DISCOVERY LABORATORIES

Discovery  Laboratories,  Inc. is a  biopharmaceutical  company  developing  its
proprietary  surfactant  technology  as  Surfactant  Replacement  Therapies  for
respiratory  diseases.  Surfactants are compositions  produced  naturally in the
lungs and essential for breathing. Discovery's technology produces an engineered
version of natural human lung  surfactant  that is designed to closely mimic the
essential  properties of human lung surfactant.  Discovery believes that through
its technology, pulmonary surfactants have the potential, for the first time, to
be developed into a series of respiratory  therapies for critical care and other
hospitalized patients where there are few or no approved therapies available.

Discovery has filed a New Drug  Application with the FDA for clearance to market
Surfaxin(r),  the Company's  lead  product,  for the  prevention of  Respiratory
Distress Syndrome in premature infants.

Discovery is currently conducting a Phase 2 clinical trial for Acute Respiratory
Distress  Syndrome in adults,  Phase 3 and Phase 2 clinical  trials for Meconium
Aspiration   Syndrome  in  full-term   infants.   With  aerosolized   surfactant
formulations,  Discovery  is  preparing  to  initiate a Phase 2 trial for asthma
(development name DSC-104) and a Phase 2 trial for Neonatal Pulmonary Disorders.

More  information  about  Discovery is available  on the  Company's  Web site at
www.DiscoveryLabs.com.

To the extent that statements in this press release are not strictly historical,
including  statements  as to  business  strategy,  outlook,  objectives,  future
milestones,  plans,  intentions,  goals,  future  financial  conditions,  future
collaboration  agreements,  the success of the  Company's  product  development,
events  conditioned on stockholder or other approval,  or otherwise as to future
events, such statements are  forward-looking,  and are made pursuant to the safe
harbor provisions of the Private  Securities  Litigation Reform Act of 1995. The
forward-looking  statements  contained  in this  release  are subject to certain
risks and  uncertainties  that could cause actual  results to differ  materially
from the  statements  made.  Among the factors  which could affect the Company's
actual  results and could cause  results to differ from those  contained  in the
forward-looking   statements  contained  herein  are  the  risk  that  financial
conditions may change,  risks relating to the progress of the Company's research
and development,  the risk that the Company will not be able to raise additional
capital or enter into additional  collaboration  agreements (including strategic
alliances for our aerosol and Surfactant Replacement  Therapies),  risk of delay
in the Company's preparation and filing of applications for regulatory approval,
risk of delay in the FDA's or other health regulatory  authorities'  approval of
any applications filed by the Company,  risks that any such regulatory authority
will not approve the marketing and sale of a drug product even after  acceptance
of an application filed by the Company for any such drug product, risks relating
to the ability of the Company's  third party contract  manufacturers  to provide
the Company  with  adequate  supplies of drug  substance  and drug  products for
completion of any of the Company's clinical studies, other risks relating to the
lack of adequate  supplies of drug  substance and drug product for completion of
any of the Company's clinical studies,  and risks relating to the development of
competing  therapies and/or  technologies by other  companies.  Companies in the
pharmaceutical and biotechnology  industries have suffered  significant setbacks
in advanced  clinical  trials,  even after  obtaining  promising  earlier  trial
results.  Data obtained from tests are  susceptible to varying  interpretations,



which may delay,  limit or prevent regulatory  approval.  Those associated risks
and others are further  described in the Company's  filings with the  Securities
and Exchange  Commission  including the most recent reports on Forms 10-K,  10-Q
and 8-K, and any amendments thereto.

Company Contacts:
John G. Cooper, EVP and CFO
Kori Beer, IR & Communications
215-340-4699